ENTITY
Innovent Biologics Inc

Innovent Biologics Inc (1801 HK)

364
Analysis
Health CareChina
Innovent Biologics, Inc. operates as a biopharmaceutical company. The Company develops, manufactures, and distributes monoclonal antibody drug candidates for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, and other diseases. Innovent Biologics serves customers in China.
more
Refresh
bullishBeiGene
03 Feb 2021 09:59

Pre-IPO BeiGene - Would the IPO on the STAR Market Be the Last Hurrah?

This article analyzed BeiGene in terms of its current pipeline, products on the market, competitive landscape, financial position, and the concerns...

Logo
272 Views
Share
30 Jan 2021 05:58

Asia Short Interest: BYD, Smoore, GCL Poly, Olympus, Nomura, Anritsu, Netmarble, UMC, Innolux, Acer

The Insight looks at large short interest movements across HK, Japan, Korea and Taiwan stocks and highlights large increases/decreases in shorts to...

Logo
292 Views
Share
bullishAdagene Inc
27 Jan 2021 09:52

Pre-IPO Adagene Inc (ADAG US) - Advanced Technology but Still Take Time for Commercialization

This article analyzed Adagene Inc. in terms of the DPL platform, the core products in the pipeline (ADG106, ADG126 and ADG116), the financial...

Logo
285 Views
Share
25 Jan 2021 09:52

China Healthcare Weekly (Jan.22)

The article analyzed the new official document for the volume-based purchase,industry viewpoints on China cryogenic storage market and “AI +...

Logo
213 Views
Share
18 Jan 2021 09:32

China Healthcare Weekly (Jan.15)

This article analyzed the new interim procedures released by NHSA, trend of blood products and biological drug market, and also include company...

Logo
389 Views
Share
x